Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

NCT03509246 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Neoplasm Epithelial
High Grade Serous Carcinoma

Interventions

DRUG: Pegylated liposomal doxorubicin plus Bortezomib

Sponsor

Seoul National University Hospital